As predictive medicine accelerates through polygenic risk scores, legal experts are raising alarms that current U.S. anti-discrimination laws may be insufficient to protect employees from genetic bias. While the Genetic Information Nondiscrimination Act (GINA) was signed into law in 2008 to prevent health insurers and employers from using genetic data to deny coverage or employment, emerging technologies that quantify complex health risks are currently testing the boundaries of these protections.
The Evolution of Predictive Health
For over a decade, GINA has served as the primary federal safeguard against genetic discrimination. The law specifically prohibits employers with 15 or more employees from requesting, requiring, or purchasing genetic information about an applicant or employee.
However, the landscape of genomic science has shifted dramatically since 2008. Polygenic risk scores (PRS) now allow researchers to estimate an individual’s susceptibility to complex conditions—such as heart disease, diabetes, or certain cancers—by aggregating data across thousands of genetic variants, rather than looking for a single disease-causing mutation.
A Regulatory Gray Area
The core of the legal debate centers on whether these risk scores fall under the legal definition of “genetic information” as codified in the 2008 legislation. Critics of the current regulatory framework argue that the law was designed to address single-gene disorders, not the probabilistic data generated by modern algorithms.
Legal scholars at institutions like Harvard and Stanford note that if an employer gains access to an employee’s risk profile, they might use that information to make subtle decisions regarding hiring or promotion. Because these scores are predictive rather than diagnostic, they exist in a legal gray area that may not trigger GINA’s explicit protections.
Industry Perspectives and Data Trends
Data from the American Society of Human Genetics indicates that the use of consumer-facing genetic testing has skyrocketed, with millions of individuals now possessing deep insights into their own biological predispositions. As this information becomes more accessible, the temptation for corporate entities to integrate such data into wellness programs or risk assessment models grows.
“The law is trailing behind the science,” says Dr. Elena Rossi, a policy analyst focusing on bioethics. “We are seeing a move toward ‘precision employment,’ where companies might claim that predictive health data is being used to optimize employee health, when in fact it could be used to screen out high-cost talent.”
